Pola-R-ICE: A phase 3 trial of combining standard R-ICE chemotherapy with polatuzumab in people with diffuse large B cell lymphoma (DLBCL)

This trial is testing the combination of standard R-ICE chemotherapy with polatuzumab in people with refractory or relapsed diffuse large b-cell lymphoma (DLBCL).

You can share the following ISRCTN.com Identifier with your medical team so they can find out more about the trial: ISRCTN13438605

Trial aim and background  

Patients with DLBCL who do not respond to initial treatment regimens are sometimes treated with an immunochemotherapy regimen called R-ICE. Unfortunately, 50% of patients will not respond to this either. The aim of this trial is to investigate the effectiveness of combining polatuzumab with standard R-ICE chemotherapy (Pola-R-ICE).

In single drug studies polatuzumab has been shown to have some benefit with little side effects, this study aims to see if this continues when given in combination with R-ICE chemotherapy. 

As a phase 3 trial patients will be divided in to two groups. One group will receive the standard regimen of R-ICE, the other group will receive Pola-R-ICE

Who can enter

Adults with DLBCL which has not responded to (refractory) or has come back after (relapsed) treatment may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • St James’ University Hospital, Leeds
  • Royal Cornwall Hospital NHS Trust, Truro
  • University College London Hospital, London
  • Southampton General Hospital, Southampton
  • Nottingham City Hospital, Nottingham
  • Christie Cancer Centre, Manchester
  • Belfast City Hospital, Belfast
  • Queen's Hospital, Romford
  • Derriford Hospital, Plymouth

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.isrctn.com/ISRCTN13438605

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.